Axio BioPharma Connects Biologics Data Across Companies

Biologics programs do not usually fail because teams collected no data. They slow down because the meaning around that data fractures as work moves from a discovery lab to a development team, a manufacturing partner, and another site.

Axio BioPharma is building from that handoff problem in two directions at once. Its Forge laboratory runs real antibody-development work in Madison, Wisconsin. Its Lattice platform is being developed to connect process context across companies without forcing every participant to surrender its data to one central system.

Founded in 2024 by CEO Justin Byers and CTO Brian Staats, Axio is making an unusual infrastructure bet: the best way to design software for biologics manufacturing is to stay close to the laboratory work that exposes where knowledge breaks.

The company recently raised a $2.4 million pre-seed round to support initial Lattice deployments and further development of Rosetta, its data-mapping layer. The financing adds fuel, but the company is still early. Lattice remains in active development, and Axio has not published scaled deployment results or quantified customer outcomes.

About Axio BioPharma

Axio BioPharma is a biomanufacturing company with an operating laboratory business and a developing data-infrastructure business.

Axio Forge is a U.S.-based, non-GMP lab focused on high-throughput monoclonal-antibody production. The company reports that Forge can produce about 100 antibodies per week with a typical turnaround of three to five weeks. Programs can begin from a sequence or plasmid and move through CHO or HEK293 expression, purification, and analytics.

Axio Lattice is the broader systems layer. It is designed to connect process information across pharma sponsors, CDMOs, laboratories, and manufacturing sites while leaving underlying data in its original environment. Instead of replacing systems such as LIMS, MES, electronic lab notebooks, historians, or quality platforms, Lattice aims to coordinate the context between them.

Together, Forge and Lattice give Axio a services base and a product-development environment. The lab generates real workflows and constraints. The software effort turns lessons from those workflows into infrastructure intended for use across organizations.

The Problem Is Context, Not Data Volume

A modern biologics program can generate extensive process, analytical, quality, and manufacturing data. The difficulty begins when the same parameter has different names, units, timestamps, or surrounding assumptions at two sites.

That inconsistency makes technology transfer slower and investigations more manual. Teams spend time reconstructing what happened, comparing documents, and resolving whether two fields describe the same thing. The data may exist, yet the decision-ready context does not travel with it.

Axio's thesis grew from direct operating experience. In a Startup Wisconsin interview, Byers described a client program that consumed 18 months and nearly $2 million before the team concluded it could not be manufactured at scale. He said the relevant information had existed but was trapped across systems and formats.

That story explains why Axio does not position artificial intelligence as the starting point. A model cannot reliably compare processes if the underlying records are disconnected or the meaning changes between organizations. The first job is to make the context usable and governed.

How Lattice Is Designed to Work

Lattice's public architecture has four named components.

Node connects to a company's local systems while leaving data in place. Rosetta standardizes terminology, structure, and context. Blueprints configure workflows for uses such as technology transfer, investigations, and monitoring. Signal is intended to surface patterns and decision support across participating environments.

The federated model matters because sponsor and manufacturing-partner data often carries ownership, security, and regulatory constraints. Centralizing everything in a new repository can create its own implementation and governance problem. Axio's proposed alternative is to let standardized meaning travel while raw data remains under the control of its owner.

The company is careful about the product's current state. It says Lattice is in active development and that it is working with select CDMO and pharma partners to define workflows and validate data models. Its published capabilities should therefore be read as direction and design, not as proof of a broadly deployed commercial platform.

Forge Keeps the Software Close to Execution

Forge is more than a separate services line. It is the operating environment behind Axio's product thesis.

The lab supports single deliverables, parallel construct screening, and iterative antibody-production programs. Axio says work runs in staggered, mixed batches rather than waiting for large project queues, and customers work directly with the scientists executing each program.

That proximity creates a useful feedback loop. Forge exposes where process context is lost, where handoffs require manual interpretation, and which data models survive contact with laboratory reality. Lattice can then be designed around observed workflows rather than an idealized diagram of how biologics manufacturing should work.

The tradeoff is focus. Running laboratory programs and building cross-company software require different operating muscles. Axio has to prove that the two lines reinforce each other instead of competing for attention and capital.

Early Ecosystem Signals

Axio is beginning to assemble external evidence around its approach.

The company was selected as a 2026 Round 1 awardee in the Innovation to Commercialization Pipeline program led by Forward BIOLABS with BioForward Wisconsin. It also announced a planned interoperability effort with The Bioforge, pairing Lattice with the BioOptima AI platform. The companies said they intend to explore coordinated workflows, proof-of-concept pilots, and joint customer opportunities.

Those announcements are useful signals, but they remain early. Planned pilots are not completed deployments, and partner intent is not the same as measured performance.

Axio has also published a 2026 to 2029 report on AI-enabled biomanufacturing. Its Biomanufacturing AI Maturity Index frames readiness across data, governance, operations, interoperability, and regulatory alignment. The framework reinforces the company's view that AI adoption is an operating-model problem as much as a model-selection problem.

Leadership Built Around Biologics and Data

Byers brings bioprocess-development and commercial experience. Staats brings more than 20 years in bioinformatics, modeling, data science, and engineering. Axio's advisory team adds experience in biologics R&D, technology transfer, manufacturing operations, and GMP commercialization.

That mix fits the problem Axio chose. Cross-company biomanufacturing infrastructure cannot be designed only as enterprise software or only as laboratory science. It has to respect the vocabulary, workflows, quality systems, and ownership boundaries of both.

Why Axio BioPharma Matters Now

Life-sciences companies are moving quickly to apply AI, but biomanufacturing still runs across organizational seams that software alone does not erase. Sponsors, CDMOs, laboratories, and technology vendors each hold part of the process record and often cannot pool everything in one place.

Axio is betting that the missing layer is not another dashboard. It is a shared way to connect meaning across those boundaries while preserving local control.

The company now has to turn a credible systems thesis into repeatable deployment evidence. The important milestones will be specific: integrations that hold up across real systems, technology transfers that require less reconstruction, investigations that begin with better context, and governance that satisfies organizations protecting valuable process knowledge.

If Axio can demonstrate those outcomes, Forge and Lattice could form a strong combination. One performs the work. The other helps the knowledge from that work travel farther than the lab where it began.